Percentage of responders for individual criteria for minimal disease activity (MDA) at baseline* and Week 24**.
| MDA Criteria | Placebo,% | Adalimumab, % |
|---|---|---|
| Tender joint count ≤ 1 | ||
| Baseline | 0 | 0 |
| Week 24 | 10.0 | 38.7 |
| Swollen joint count ≤ 1 | ||
| Baseline | 0 | 0 |
| Week 24 | 13.3 | 32.3 |
| Patient global assessment of disease activity ≤ 20 | ||
| Baseline | 14.7 | 17.9 |
| Week 24 | 18.3 | 50.0 |
| Pain ≤ 15 | ||
| Baseline | 8.8 | 6.0 |
| Week 24 | 11.7 | 48.4 |
| Health Assessment Questionnaire ≤ 0.5 | ||
| Baseline | 27.5 | 23.9 |
| Week 24 | 35.0 | 51.6 |
| Enthesitis ≤ 1*** | ||
| Baseline | 68.1 | 75.4 |
| Week 24 | 66.7 | 82.0 |
| Psoriasis Activity and Severity Index ≤ 1 | ||
| Baseline | 4.4 | 1.5 |
| Week 24 | 3.4 | 59.7 |
| Physician global assessment “Clear” | ||
| Baseline | 0 | 0 |
| Week 24 | 0 | 33.9 |
| Physician global assessment “Clear” or “Almost clear” | ||
| Baseline | 1.5 | 1.5 |
| Week 24 | 12.1 | 72.6 |